Drug intelligence / Profile preview

IDC2502

Development stage: Preclinical
Lead developer: Prestige Biopharma
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous, Intravenous

Overview

IDC2502 is a monoclonal antibody biosimilar candidate being developed by Prestige Biopharma (PBK). It is designed to target the p19 subunit of interleukin-23 (IL-23), a cytokine that plays a central role in the pathogenesis of several immune-mediated inflammatory diseases. By blocking IL-23, the drug inhibits the activation and maintenance of Th17 cells, thereby reducing the production of pro-inflammatory cytokines like IL-17 and IL-22. As a biosimilar to risankizumab (Skyrizi), IDC2502 is intended for the treatment of conditions such as plaque psoriasis and Crohn's disease. It is currently in the preclinical stage of development.

Other names: risankizumab biosimilarPBK risankizumab biosimilar

Targets

IL23A (Interleukin-23 p19 Subunit)

Beyond the preview

Go deeper on IDC2502.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IDC2502.

Explore the full profile